Article | Published:

Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme

Nature Chemical Biologyvolume 15pages565574 (2019) | Download Citation

Abstract

Enzymes that act on multiple substrates are common in biology but pose unique challenges as therapeutic targets. The metalloprotease insulin-degrading enzyme (IDE) modulates blood glucose levels by cleaving insulin, a hormone that promotes glucose clearance. However, IDE also degrades glucagon, a hormone that elevates glucose levels and opposes the effect of insulin. IDE inhibitors to treat diabetes, therefore, should prevent IDE-mediated insulin degradation, but not glucagon degradation, in contrast with traditional modes of enzyme inhibition. Using a high-throughput screen for non-active-site ligands, we discovered potent and highly specific small-molecule inhibitors that alter IDE’s substrate selectivity. X-ray co-crystal structures, including an IDE-ligand-glucagon ternary complex, revealed substrate-dependent interactions that enable these inhibitors to potently block insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations. These findings suggest a path for developing IDE-targeting therapeutics, and offer a blueprint for modulating other enzymes in a substrate-selective manner to unlock their therapeutic potential.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Data availability

Complete results of the IDE high-throughput screens and the IDE inhibition counter-screen are available in the PubChem BioAssay database (1259348, 1259349), the IDE–37, IDE–63 and the IDE–63–glucagon X-ray structures are available in the PDB (PDB IDs 6BYZ, 6MQ3 and 6EDS, respectively).

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Mirsky, I. A. & Broh-Kahn, R. H. The inactivation of insulin by tissue extracts; the distribution and properties of insulin inactivating extracts. Arch. Biochem. 20, 1–9 (1949).

  2. 2.

    Duckworth, W. C. & Kitabchi, A. E. Insulin and glucagon degradation by the same enzyme. Diabetes 23, 536–543 (1974).

  3. 3.

    Roglic, G. & World Health Organization. Global Report on Diabetes (World Health Organization, 2016).

  4. 4.

    Costes, S. & Butler, P. C. Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes? Cell. Metab. 20, 201–203 (2014).

  5. 5.

    Tang, W. J. Targeting insulin-degrading enzyme to treat type 2 diabetes mellitus. Trends Endocrinol. Metab. 27, 24–34 (2016).

  6. 6.

    Duckworth, W. C., Bennett, R. G. & Hamel, F. G. Insulin degradation: progress and potential. Endocr. Rev. 19, 608–624 (1998).

  7. 7.

    Abdul-Hay, S. O. et al. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PLoS One 6, e20818 (2011).

  8. 8.

    Farris, W. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100, 4162–4167 (2003).

  9. 9.

    Villa-Perez, P. et al. Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. Metab. Clin. Exp. 88, 1–11 (2018).

  10. 10.

    Steneberg, P. et al. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of alpha-synuclein levels in beta-cells. Diabetes 62, 2004–2014 (2013).

  11. 11.

    Maianti, J. P. et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature 511, 94–98 (2014).

  12. 12.

    Durham, T. B. et al. Dual exosite-binding inhibitors of insulin-degrading enzyme challenge its role as the primary mediator of insulin clearance in vivo. J. Biol. Chem. 290, 20044–20059 (2015).

  13. 13.

    Ahren, B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc. Health Risk Manag. 9, 155–163 (2013).

  14. 14.

    Bennett, R. G., Duckworth, W. C. & Hamel, F. G. Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem. 275, 36621–36625 (2000).

  15. 15.

    Malito, E., Hulse, R. E. & Tang, W. J. Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 65, 2574–2585 (2008).

  16. 16.

    Unger, R. H. & Cherrington, A. D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Inv. 122, 4–12 (2012).

  17. 17.

    Drag, M. & Salvesen, G. S. Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 9, 690–701 (2010).

  18. 18.

    Berg, D. T., Wiley, M. R. & Grinnell, B. W. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Science 273, 1389–1391 (1996).

  19. 19.

    Xu, X., Chen, Z., Wang, Y., Bonewald, L. & Steffensen, B. Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. Biochem. J. 406, 147–155 (2007).

  20. 20.

    Knapinska, A. M. et al. SAR studies of exosite-binding substrate-selective inhibitors of A disintegrin and metalloprotease 17 (ADAM17) and application as selective in vitro probes. J. Med. Chem. 58, 5808–5824 (2015).

  21. 21.

    Madoux, F. et al. Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate. Sci. Rep. 6, 11 (2016).

  22. 22.

    Panwar, P. et al. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone. Br. J. Pharmacol. 175, 902–923 (2018).

  23. 23.

    Leissring, M. A. et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS ONE 5, e10504 (2010).

  24. 24.

    Deprez-Poulain, R. et al. Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice. Nat. Comm. 6, 8250 (2015).

  25. 25.

    Hendriks, B. S., Seidl, K. M. & Chabot, J. R. Two additive mechanisms impair the differentiation of ‘substrate-selective’ p38 inhibitors from classical p38 inhibitors in vitro. BMC Syst. Biol. 4, 23 (2010).

  26. 26.

    Abdul-Hay, S. O. et al. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. J. Med. Chem. 56, 2246–2255 (2013).

  27. 27.

    Charton, J. et al. Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-beta hydrolysis. Eur. J. Med. Chem. 79, 184–193 (2014).

  28. 28.

    Abdul-Hay, S. O. et al. Selective targeting of extracellular insulin-degrading enzyme by quasi-irreversible thiol-modifying inhibitors. ACS Chem. Biol. 10, 2716–2724 (2015).

  29. 29.

    Charton, J. et al. Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme. Eur. J. Med. Chem. 90, 547–567 (2015).

  30. 30.

    Busschots, K. et al. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem. Biol. 19, 1152–1163 (2012).

  31. 31.

    Rettenmaier, T. J. et al. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Proc. Natl Acad. Sci. USA 111, 18590–18595 (2014).

  32. 32.

    Shah, N. G. et al. Novel noncatalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-Inflammatory activity. J. Immunol. 198, 3296–3306 (2017).

  33. 33.

    Hall, M. D. et al. Fluorescence polarization assays in high-throughput screening and drug discovery: a review. Methods Appl. Fluoresc. 4, 022001 (2016).

  34. 34.

    Lowe, J. T. et al. Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. J. Org. Chem. 77, 7187–7211 (2012).

  35. 35.

    Malito, E. et al. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme. Biochemistry 47, 12822–12834 (2008).

  36. 36.

    Sebaugh, J. L. Guidelines for accurate EC50/IC50 estimation. Pharm. Stat. 10, 128–134 (2011).

  37. 37.

    Degorce, F. et al. HTRF: A technology tailored for drug discovery—a review of theoretical aspects and recent applications. Curr. Chem. Genomics 3, 22–32 (2009).

  38. 38.

    Leung, C. S., Leung, S. S., Tirado-Rives, J. & Jorgensen, W. L. Methyl effects on protein-ligand binding. J. Med. Chem. 55, 4489–4500 (2012).

  39. 39.

    Shroyer, L. A. & Varandani, P. T. Purification and characterization of a rat liver cytosol neutral thiol peptidase that degrades glucagon, insulin, and isolated insulin A and B chains. Arch. Biochem. Biophys. 236, 205–219 (1985).

  40. 40.

    Shen, Y., Joachimiak, A., Rosner, M. R. & Tang, W. J. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443, 870–874 (2006).

  41. 41.

    Leissring, M. A. & Selkoe, D. J. Structural biology: enzyme target to latch on to. Nature 443, 761–762 (2006).

  42. 42.

    McCord, L. A. et al. Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme. Proc. Natl Acad. Sci. USA 110, 13827–13832 (2013).

  43. 43.

    Song, E. S., Juliano, M. A., Juliano, L. & Hersh, L. B. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J. Biol. Chem. 278, 49789–49794 (2003).

  44. 44.

    Im, H. et al. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J. Biol. Chem. 282, 25453–25463 (2007).

  45. 45.

    Song, E. S., Rodgers, D. W. & Hersh, L. B. A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties. PLoS One 5, e9719 (2010).

  46. 46.

    Duggan, K. C. et al. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat. Chem. Biol. 7, 803–809 (2011).

  47. 47.

    Rose, K. et al. Insulin proteinase liberates from glucagon a fragment known to have enhanced activity against Ca2+ + Mg2+-dependent ATPase. Biochem. J. 256, 847–851 (1988).

  48. 48.

    Vandenbroucke, R. E. & Libert, C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat. Rev. Drug Discov. 13, 904–927 (2014).

  49. 49.

    McMurray, J. J. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur. J. Heart Fail. 17, 242–247 (2015).

  50. 50.

    Zeke, A. et al. Systematic discovery of linear binding motifs targeting an ancient protein interaction surface on MAP kinases. Mol. Syst. Biol. 11, 837 (2015).

  51. 51.

    Geu-Flores, F., Nour-Eldin, H. H., Nielsen, M. T. & Halkier, B. A. USER fusion: a rapid and efficient method for simultaneous fusion and cloning of multiple PCR products. Nucleic Acid. Res. 35, e55 (2007).

  52. 52.

    Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D 67, 293–302 (2011).

  53. 53.

    McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).

  54. 54.

    Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).

  55. 55.

    Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).

  56. 56.

    APEX2 v.2014.11-0 (Bruker AXS, Madison, WI, USA, 2014).

  57. 57.

    Krause, L., Herbst-Irmer, R., Sheldrick, G. M. & Stalke, D. Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination. J. Appl. Crystallogr. 48, 3–10 (2015).

  58. 58.

    Sheldrick, G. M. SHELXT—integrated space-group and crystal-structure determination. Acta Crystallogr. A 71, 3–8 (2015).

  59. 59.

    Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. C 71, 3–8 (2015).

  60. 60.

    Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. App. Crystallogr. 42, 339–341 (2009).

Download references

Acknowledgements

We thank A. Saghatelian, S. Schreiber and M. Morningstar for helpful discussions. We are grateful to S. Trauger and J. Wang for mass spectrometry assistance. We thank J. Bittker, M. Wawer and V. Dancik for assistance with library management and analysis. We thank Z. Foda and A. Lyczek for ligand docking studies and D. Dobrovolsky for assistance with assays. We thank S.-L. Zheng for small-molecule structural determination. IDE X-ray diffraction data were collected at ALS (operated by LBNL) and NSLS2 (operated by BNL) on behalf of DOE and this is supported by DOE Office of Biological and Environmental Research (KP1605010) and NIH (R01GM105404, S10OD018483, P41GM111244). This research was supported by the NIH grant nos. R35 GM118062 (to D.R.L.), R01 EB022376 (to D.R.L.), R35 GM119437 (to M.A.S.), R56 DK106200 (to M.A.S.) and the Howard Hughes Medical Institute (to D.R.L.). The Fonds de Recherche en Santé du Québec and Alfred Bader Fund provided fellowship support to J.P.M.

Author information

Author notes

  1. These authors contributed equally: Juan Pablo Maianti, Grace A. Tan.

Affiliations

  1. Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA

    • Juan Pablo Maianti
    •  & David R. Liu
  2. Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA

    • Juan Pablo Maianti
    •  & David R. Liu
  3. Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA

    • Juan Pablo Maianti
    •  & David R. Liu
  4. Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA

    • Juan Pablo Maianti
    • , Amedeo Vetere
    • , Bridget K. Wagner
    •  & David R. Liu
  5. Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA

    • Grace A. Tan
    • , Amie J. Welsh
    •  & Markus A. Seeliger

Authors

  1. Search for Juan Pablo Maianti in:

  2. Search for Grace A. Tan in:

  3. Search for Amedeo Vetere in:

  4. Search for Amie J. Welsh in:

  5. Search for Bridget K. Wagner in:

  6. Search for Markus A. Seeliger in:

  7. Search for David R. Liu in:

Contributions

J.P.M. designed the exo-site screen, expressed proteins, synthesized the SSIs and ran biochemistry assays. G.A.T. co-crystallized and solved the IDE X-ray structures with A.J.W.’s assistance. A.V. optimized screen analysis. B.K.W. supervised the screen. M.A.S. and D.R.L. supervised the research program. All authors contributed to the writing of the manuscript.

Competing interests

J.P.M. and D.R.L. are co-inventors on patents and patent applications based on this work, and are co-founders of Exo Therapeutics, a small-molecule drug discovery company.

Corresponding authors

Correspondence to Markus A. Seeliger or David R. Liu.

Supplementary information

  1. Supplementary Information

    Supplementary Tables 1–9, Supplementary Figures 1–6

  2. Reporting Summary

  3. Supplementary Note

    Synthetic protocols

  4. Supplementary Video

    Supplementary animation generated using PyMOL (1,000 frames).

  5. Supplementary Data Set 1

    Supplementary data deposited in PubMed BioAssay (numbers 1259349 and 1259348).

  6. Supplementary Data Set 2

    Supplementary reports and data provided by EuroFins (Belgium) that is summarized in Supplementary Table 6.

  7. Supplementary Data Set 3

    Nuclear Magnetic Resonance spectra (1H-, 13C-, and 19F-NMR).

About this article

Publication history

Received

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/s41589-019-0271-0